LONDON (Reuters) - Roche's cancer drug MabThera has been recommended for use on the NHS as a maintenance therapy for patients with follicular non-Hodgkin's lymphoma, expanding the market for the medicine.
Source: http://uk.reuters.com/article/2011/05/23/uk-roche-britain-idUKTRE74M6WP20110523?feedType=RSS&feedName=domesticNews
current affairs beauty computers technology
No comments:
Post a Comment